文献速递结核与非结核分枝杆菌细菌感染、耐药与抗菌药物

南非耐药结核患者氨基糖苷类致听力损失的预测模型

Aminoglycoside-induced Hearing Loss Among Patients Being Treated for Drug-resistant Tuberculosis in South Africa: A Prediction Model.
PubMed 文献 · Clin Infect Dis · 2020-01-01

本研究基于南非379例接受氨基糖苷类(AGs)治疗的耐药结核(DR-TB)成人队列,开发并验证了预测AGs致听力损失的临床模型。63%的参与者出现听力损失。在80%预测概率阈值下,阳性预测值为83%,阴性预测值为40%。该模型有助于识别高风险患者,优先使用避免AGs的方案。

要点

  • 63%的DR-TB患者在接受AGs治疗6个月内出现听力损失。
  • 预测模型纳入每周AG剂量、HIV状态及CD4计数、年龄、血清白蛋白、BMI和既往听力损失。
  • 模型对250-8000 Hz听力损失的AUC为0.71,在80%阈值下阳性预测值83%。

核心结论

  • 该模型可识别DR-TB患者中AGs致耳毒性高风险者,有助于在资源有限地区优先选用避免AGs的方案。

研究设计与样本

  • 嵌套前瞻性队列研究,纳入379例南非确诊DR-TB并接受AGs为基础方案治疗的成人,采用多因素logistic回归开发预测模型。

主要发现

  • 63%(n=238)的参与者出现任何程度的听力损失。
  • 预测250-8000 Hz听力损失的模型纳入每周AG剂量、HIV状态及CD4计数、年龄、血清白蛋白、体重指数和既往听力损失。
  • 在80%预测概率阈值下,阳性预测值为83%,阴性预测值为40%。
  • 模型对超高频听力损失(>9000 Hz)的区分度相似(AUC=0.81),但对临床确定的听力损失区分度较弱(AUC=0.60)。

临床怎么用

  • 在临床中可考虑使用该模型评估DR-TB患者AGs致听力损失风险,以优先安排AGs避免方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Individuals treated for drug-resistant tuberculosis (DR-TB) with aminoglycosides (AGs) in resource-limited settings often experience permanent hearing loss, yet there is no practical method to identify those at higher risk. We sought to develop a clinical prediction model of AG-induced hearing loss among patients initiating DR-TB treatment in South Africa. METHODS: Using nested, prospective data from a cohort of 379 South African adults being treated for confirmed DR-TB with AG-based regimens we developed the prediction model using multiple logistic regression. Predictors were collected from clinical, audiological, and laboratory evaluations conducted at the initiation of DR-TB treatment. The outcome of AG-induced hearing loss was identified from audiometric and clinical evaluation by a worsened hearing threshold compared with baseline during the 6-month intensive phase. RESULTS: Sixty-three percent of participants (n = 238) developed any level of hearing loss. The model predicting hearing loss at frequencies from 250 to 8000 Hz included weekly AG dose, human immunodeficiency virus status with CD4 count, age, serum albumin, body mass index, and pre-existing hearing loss. This model demonstrated reasonable discrimination (area under the receiver operating characteristic curve [AUC] = 0.71) and calibration (χ2[8] = 6.10, P = .636). Using a cutoff of 80% predicted probability of hearing loss, the positive predictive value of this model was 83% and negative predictive value was 40%. Model discrimination was similar for ultrahigh-frequency hearing loss (frequencies >9000 Hz; AUC = 0.81) but weaker for clinically determined hearing loss (AUC = 0.60). CONCLUSIONS: This model may identify patients with DR-TB who are at highest risk of developing AG-induced ototoxicity and may help prioritize patients for AG-sparing regimens in clinical settings where access is limited.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Hong H, Dowdy DW, Dooley KE, et al. Aminoglycoside-induced Hearing Loss Among Patients Being Treated for Drug-resistant Tuberculosis in South Africa: A Prediction Model. Clin Infect Dis. 2020. PMID: 30963176. doi:10.1093/cid/ciz289

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。